TSX:EXEHealthcare
A Look At Extendicare’s Valuation As Q1 2026 Results And Dividend Hike Draw Investor Interest
Q1 results and dividend move put Extendicare in focus
Extendicare (TSX:EXE) has jumped onto many investors’ radar after its first quarter 2026 results, a higher monthly dividend, and fresh financing tied to a series of home health care acquisitions.
See our latest analysis for Extendicare.
At around CA$30.20, the stock has been on a strong run, with a 30 day share price return of 6.56% and a 1 year total shareholder return of 119.02%. This suggests momentum has been building around the...